AMNIOX Medical, Inc., a TissueTech, Inc., company, announced the results of A Single-Center, Retrospective Study of Cryopreserved Umbilical Cord for Wound Healing in Patients Suffering From Chronic Wounds of the Foot and Ankle, a review of the effectiveness of NEOX® Wound Allograft in treating this patient population.
Netsertive, a digital marketing intelligence company that enables brands and their local channel partners with turnkey, co-op compliant digital marketing capabilities, bringing them together to win local customers, today announced it ranked 128 on Deloitte’s Technology Fast 500™.
The most comprehensive location marketing measurement tool available, Velocity Insights moves beyond simple performance metrics to provide the actionable analysis enterprise marketers need to improve the effectiveness of their local marketing efforts.
Netsertive, a digital marketing intelligence company that brings brands and local businesses together to win local customers, today announced continued growth within the automotive vertical. Contributing to this growth, Netsertive was selected as one of six Kia Certified Website and Digital Advertising providers, a program that kicked off in September 2015 at the Kia National Dealer Meeting in Las Vegas, NV.
Inaugural awards honor top Innovators in hyperlocal marketing industry.
Fast-growing firm to further innovate its brand-to-local digital marketing platform to fuel continued growth.
“This financing allows us to build on the incredible market demand by further expanding our platform capabilities and making an impact in more healthcare organizations.”
A New Haven company that develops software to help banks and credit unions comply with regulations that govern the industry was crowned as the top tech company in Connecticut during ceremonies Thursday night at the Oakdale Theater.The selection of Continuity as the overall winner of the Marcum Tech Top 40 was based upon the Elm […]
Veran Medical Technologies Inc., a privately-held medical device company and leader in image-guided endobronchial and percutaneous technology for diagnosis of lung cancer and therapy delivery, has completed a $30.6 million financing, led by Versant Ventures and River Cities Capital Funds.
On June 5, EndoChoice Holdings Inc. (NYSE:GI), completed an IPO, raising nearly $106 million on the New York Stock Exchange. River Cities Fund IV first invested in EndoChoice in 2008 and is the second-largest stakeholder in the company.